Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Spain flag Spain · Delayed Price · Currency is EUR
55.25
-0.50 (-0.90%)
Jul 30, 2025, 4:11 PM CET
-0.90%
Market Cap2.85B
Revenue (ttm)749.00M
Net Income (ttm)132.27M
Shares Out51.15M
EPS (ttm)2.59
PE Ratio21.55
Forward PE19.10
Dividend0.94 (1.64%)
Ex-Dividend DateJul 14, 2025
Volume52,718
Average Volume145,205
Open55.85
Previous Close55.75
Day's Range55.10 - 56.40
52-Week Range45.52 - 89.45
Beta0.45
RSI51.74
Earnings DateJul 24, 2025

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,... [Read more]

Sector Healthcare
Founded 1946
Employees 2,197
Stock Exchange Madrid Stock Exchange
Ticker Symbol ROVI
Full Company Profile

Financial Performance

In 2024, BME:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.

Financial Statements

News

Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q4 2024 Earnings Call Highlights: Navigating ...

Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing Growth Opportunities

5 months ago - GuruFocus